Illumina Focuses on Bringing NGS Tests to Market in Second Half of 2015 | GenomeWeb

NEW YORK (GenomeWeb) – As clinical and translational customers make up an increasing percentage of Illumina's customer base, the firm is looking to launch a number of next-generation sequencing-based tests this year in the oncology and reproductive health space.

In addition, the company continues to make improvements to its fleet of NGS systems, including the recently launched SeqLab solution for HiSeq X customers and the full commercial launch of automated sample prep system NeoPrep.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.